These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26009024)

  • 1. Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.
    Anywaine Z; Abaasa A; Levin J; Kasirye R; Kamali A; Grosskurth H; Munderi P; Nunn A
    Contemp Clin Trials; 2015 Jul; 43():100-4. PubMed ID: 26009024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.
    Kasirye R; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    Malar J; 2016 Jul; 15():361. PubMed ID: 27417903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
    Anywaine Z; Levin J; Kasirye R; Lutaakome JK; Abaasa A; Nunn A; Grosskurth H; Munderi P;
    PLoS One; 2018; 13(12):e0206907. PubMed ID: 30596666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.
    Kasirye RP; Baisley K; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Grosskurth H
    AIDS; 2016 Feb; 30(4):635-44. PubMed ID: 26558729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
    Laurens MB; Mungwira RG; Nyirenda OM; Divala TH; Kanjala M; Muwalo F; Mkandawire FA; Tsirizani L; Nyangulu W; Mwinjiwa E; Taylor TE; Mallewa J; Blackwelder WC; Plowe CV; Laufer MK; van Oosterhout JJ
    Trials; 2016 Jul; 17(1):322. PubMed ID: 27431995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cotrimoxazole prophylaxis on
    Jiang J; Qin F; Meng S; Nehl EJ; Huang J; Liu Y; Zou J; Dong W; Huang J; Chen H; Zang N; Liang B; Ning C; Liao Y; Luo C; Liu H; Liu X; Wang J; Zhou O; Le T; Ye L; Wu F; Liang H
    Emerg Microbes Infect; 2019; 8(1):367-376. PubMed ID: 31851879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy.
    Kyosiimire-Lugemwa J; Anywaine Z; Abaasa A; Levin J; Gombe B; Musinguzi K; Kaleebu P; Grosskurth H; Munderi P; Pala P
    J Infect Dis; 2020 Jul; 222(3):381-390. PubMed ID: 31714954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
    Walker AS; Ford D; Gilks CF; Munderi P; Ssali F; Reid A; Katabira E; Grosskurth H; Mugyenyi P; Hakim J; Darbyshire JH; Gibb DM; Babiker AG
    Lancet; 2010 Apr; 375(9722):1278-86. PubMed ID: 20347483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
    Polyak CS; Yuhas K; Singa B; Khaemba M; Walson J; Richardson BA; John-Stewart G
    PLoS Med; 2016 Jan; 13(1):e1001934. PubMed ID: 26731191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda.
    Watera C; Todd J; Muwonge R; Whitworth J; Nakiyingi-Miiro J; Brink A; Miiro G; Antvelink L; Kamali A; French N; Mermin J
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):373-8. PubMed ID: 16810124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.
    Kasirye RP; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    AIDS; 2017 Feb; 31(4):577-582. PubMed ID: 28121670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of vitamin D
    Sudfeld CR; Mugusi F; Aboud S; Nagu TJ; Wang M; Fawzi WW
    Trials; 2017 Feb; 18(1):66. PubMed ID: 28183335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
    Hakim J; Musiime V; Szubert AJ; Mallewa J; Siika A; Agutu C; Walker S; Pett SL; Bwakura-Dangarembizi M; Lugemwa A; Kaunda S; Karoney M; Musoro G; Kabahenda S; Nathoo K; Maitland K; Griffiths A; Thomason MJ; Kityo C; Mugyenyi P; Prendergast AJ; Walker AS; Gibb DM;
    N Engl J Med; 2017 Jul; 377(3):233-245. PubMed ID: 28723333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
    Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.
    Suthar AB; Vitoria MA; Nagata JM; Anglaret X; Mbori-Ngacha D; Sued O; Kaplan JE; Doherty MC
    Lancet HIV; 2015 Apr; 2(4):e137-50. PubMed ID: 26424674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.
    Saadani Hassani A; Marston BJ; Kaplan JE
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S257-69. PubMed ID: 25768865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does cotrimoxazole prophylaxis in HIV patients increase the drug resistance of pneumococci? A comparative cross-sectional study in southern Ethiopia.
    Seid M; Beyene G; Alemu Y; Workalemahu B; Delbo M; Taddesse D; Biresaw G; Manilal A
    PLoS One; 2020; 15(12):e0243054. PubMed ID: 33284828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Anti-Retroviral Treatment and Cotrimoxazole Prophylaxis on Helminth Infections in HIV-Infected Patients in Lambaréné, Gabon.
    Janssen S; Hermans S; Knap M; Moekotte A; Rossatanga EG; Adegnika AA; Bélard S; Hänscheid T; Grobusch MP
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003769. PubMed ID: 25993501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
    Bwakura-Dangarembizi M; Kendall L; Bakeera-Kitaka S; Nahirya-Ntege P; Keishanyu R; Nathoo K; Spyer MJ; Kekitiinwa A; Lutaakome J; Mhute T; Kasirye P; Munderi P; Musiime V; Gibb DM; Walker AS; Prendergast AJ
    N Engl J Med; 2014 Jan; 370(1):41-53. PubMed ID: 24382064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.